Drugs - Real World Outcomes · 2021 · 17 citations · 15 references
MedicineObstetricsPharmacologyClinical PharmacologyMaternal-fetal MedicinePharmacovigilanceAdverse Drug Event ReportingAdverse Drug Reaction ReportingMaternal Medical Complications In PregnancyPregnancyReproductive PharmacologySpontaneous Reporting SystemsAdverse Drug EventsMaternal Drug SafetyPharmacovigilance In PregnancyPregnancy Adverse Drug Reaction ReportingPregnancy Loss RiskSafety Signal DetectionSafety Signal IdentificationSpontaneous Report Databases
BACKGROUND: There is limited research regarding the use of glaucoma medicines during pregnancy. Prostaglandins contract uterine smooth muscle; however, it is not clear whether prostaglandin eye drops are associated with pregnancy loss in pregnant women. OBJECTIVES: We conducted a pharmacovigilance study using spontaneous report databases from Japan and the USA to evaluate the association between pregnancy loss and the use of prostaglandin eye drops during pregnancy. METHODS: The Japanese Adverse Drug Event Report database and the Food and Drug Administration Adverse Event Reporting System were used for analysis. Disproportionality analyses and a review of individual case safety reports were conducted. RESULTS: As for prostaglandin eye drops in pregnancy-related reports, there were eight reports involving latanoprost in the Japanese Adverse Drug Event Report database and no reports of pregnant women using other prostaglandin eye drops. In the Food and Drug Administration Adverse Event Reporting System, there were 25 reports involving latanoprost, 23 involving bimatoprost, 13 involving travoprost, and three involving tafluprost. The drug safety signal was detected during latanoprost usage and pregnancy loss. In the Japanese Adverse Drug Event Report database, there were five reports of pregnancy loss related to latanoprost, with a reporting odds ratio of 12.84 (95% confidence interval 3.06-53.86), and in the Food and Drug Administration Adverse Event Reporting System, pregnancy loss was reported in 12 cases of latanoprost usage with a reporting odds ratio of 4.35 (95% confidence interval 1.98-9.54). Uterine contractions were observed as concomitant adverse events in one case. CONCLUSIONS: Although a disproportionality analysis cannot determine causality, we need to keep an eye on the signal detected in this study. This signal should be validated using a causal design study.
15
Good Signal Detection Practices: Evidence from IMI PROTECT
A Wisniewski, Andrew Bate, Cédric Bousquet et al. · Drug Safety · 2016 · 144 citations · Full text
Latanoprost exposure in pregnancy
Marco De Santis, Angela Lucchese, Brigida Carducci et al. · American Journal of Ophthalmology · 2004 · 75 citations
Topical timolol therapy in pregnancy: Is it safe for the fetus?
A.M. Wagenvoort, J. M. G. van Vugt, M. R. Sobotka et al. · Teratology · 1998 · 68 citations